These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 30287523)

  • 21. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
    Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
    Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
    Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.
    Lampson BL; Kim HT; Davids MS; Abramson JS; Freedman AS; Jacobson CA; Armand PA; Joyce RM; Arnason JE; Rassenti LZ; Kipps TJ; Fein J; Fernandes SM; Hanna JR; Fisher DC; Brown JR
    Blood Adv; 2019 Apr; 3(7):1167-1174. PubMed ID: 30967392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia
    Davids MS; Kim HT; Yu L; De Maeyer G; McDonough M; Vartanov AR; Langey R; Fernandes SM; Hellman JM; Francoeur K; Arnason J; Jacobsen ED; LaCasce AS; Fisher DC; Brown JR
    Leuk Lymphoma; 2019 May; 60(5):1312-1315. PubMed ID: 30322319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
    Jaglowski SM; Jones JA; Nagar V; Flynn JM; Andritsos LA; Maddocks KJ; Woyach JA; Blum KA; Grever MR; Smucker K; Ruppert AS; Heerema NA; Lozanski G; Stefanos M; Munneke B; West JS; Neuenburg JK; James DF; Hall N; Johnson AJ; Byrd JC
    Blood; 2015 Aug; 126(7):842-50. PubMed ID: 26116658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
    Zelenetz AD; Barrientos JC; Brown JR; Coiffier B; Delgado J; Egyed M; Ghia P; Illés Á; Jurczak W; Marlton P; Montillo M; Morschhauser F; Pristupa AS; Robak T; Sharman JP; Simpson D; Smolej L; Tausch E; Adewoye AH; Dreiling LK; Kim Y; Stilgenbauer S; Hillmen P
    Lancet Oncol; 2017 Mar; 18(3):297-311. PubMed ID: 28139405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy.
    Nikolaenko L; Liu T; Danilov AV
    Expert Rev Anticancer Ther; 2021 May; 21(5):481-488. PubMed ID: 33499685
    [No Abstract]   [Full Text] [Related]  

  • 29. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
    Davids MS; Hallek M; Wierda W; Roberts AW; Stilgenbauer S; Jones JA; Gerecitano JF; Kim SY; Potluri J; Busman T; Best A; Verdugo ME; Cerri E; Desai M; Hillmen P; Seymour JF
    Clin Cancer Res; 2018 Sep; 24(18):4371-4379. PubMed ID: 29895707
    [No Abstract]   [Full Text] [Related]  

  • 30. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
    Farooqui MZ; Valdez J; Martyr S; Aue G; Saba N; Niemann CU; Herman SE; Tian X; Marti G; Soto S; Hughes TE; Jones J; Lipsky A; Pittaluga S; Stetler-Stevenson M; Yuan C; Lee YS; Pedersen LB; Geisler CH; Calvo KR; Arthur DC; Maric I; Childs R; Young NS; Wiestner A
    Lancet Oncol; 2015 Feb; 16(2):169-76. PubMed ID: 25555420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.
    Davids MS; Fisher DC; Tyekucheva S; McDonough M; Hanna J; Lee B; Francoeur K; Montegaard J; Odejide O; Armand P; Arnason J; Brown JR
    Leukemia; 2021 Apr; 35(4):1064-1072. PubMed ID: 32820271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Barrientos JC; O'Brien S; Brown JR; Kay NE; Reddy NM; Coutre S; Tam C; Mulligan S; Jaeger U; Devereux S; Pocock C; Robak T; Schuster SJ; Schuh A; Gill D; Bloor A; Dearden C; Moreno C; Cull G; Hamblin M; Jones JA; Eckert K; Solman IG; Suzuki S; Hsu E; James DF; Byrd JC; Hillmen P
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):803-813.e7. PubMed ID: 30249389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.
    van Oers MH; Kuliczkowski K; Smolej L; Petrini M; Offner F; Grosicki S; Levin MD; Gupta I; Phillips J; Williams V; Manson S; Lisby S; Geisler C;
    Lancet Oncol; 2015 Oct; 16(13):1370-9. PubMed ID: 26377300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Ujjani C; Ramzi P; Gehan E; Wang H; Wang Y; Cheson BD
    Leuk Lymphoma; 2015 Apr; 56(4):915-20. PubMed ID: 24925211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II study of induction followed by intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
    Shouse G; Chen L; Siddiqi T; Muir A; Brown JR; Spurgeon SE; Danilov AV
    Leuk Lymphoma; 2024 Oct; 65(10):1516-1519. PubMed ID: 38836342
    [No Abstract]   [Full Text] [Related]  

  • 36. Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.
    Howard DR; Munir T; Hockaday A; Rawstron AC; Collett L; Oughton JB; Allsup D; Bloor A; Phillips D; Hillmen P
    Trials; 2016 Sep; 17(1):456. PubMed ID: 27645620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.
    Flinn IW; Patel M; Oki Y; Horwitz S; Foss FF; Allen K; Douglas M; Stern H; Sweeney J; Kharidia J; Kelly P; Kelly VM; Kahl B
    Am J Hematol; 2018 Nov; 93(11):1311-1317. PubMed ID: 30033575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Duvelisib: First Global Approval.
    Blair HA
    Drugs; 2018 Nov; 78(17):1847-1853. PubMed ID: 30430368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.
    Stilgenbauer S; Eichhorst B; Schetelig J; Hillmen P; Seymour JF; Coutre S; Jurczak W; Mulligan SP; Schuh A; Assouline S; Wendtner CM; Roberts AW; Davids MS; Bloehdorn J; Munir T; Böttcher S; Zhou L; Salem AH; Desai M; Chyla B; Arzt J; Kim SY; Verdugo M; Gordon G; Hallek M; Wierda WG
    J Clin Oncol; 2018 Jul; 36(19):1973-1980. PubMed ID: 29715056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.
    Vangapandu HV; Jain N; Gandhi V
    Expert Opin Investig Drugs; 2017 May; 26(5):625-632. PubMed ID: 28388280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.